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JAK2 V617F mutation, mesenteric vein
thrombosis, and myeloproliferative disorders
Christopher D. Owens, MD, MSc, San Francisco, Calif
Mesenteric vein thrombosis is a rare disorder that is often the first manifestation of a systemic condition such as a
hypercoagulable state or cancer. In particular, myeloproliferative disorders can present as mesenteric vein thrombosis
even in the setting of relatively normal peripheral blood counts. A recent novel mutation in the Janus activated kinase 2
gene involving a gain-of-function substitute of valine to phenylalanine at position 617 (JAK2 V617F) has been discovered
to be prevalent in patients with mesenteric vein thrombosis andmyeloproliferative disorders. This article reports a patient
who presented with mesenteric vein thrombosis and relatively normal peripheral blood counts. He was diagnosed with
essential thrombocythemia after he tested positive for the JAK2 V617F mutation. (J Vasc Surg 2010;52:205-7.)Mesenteric venous thrombosis (MVT) involving the
mesenteric, splenic, or the portal vein is a rare disorder
with a broad range of clinical manifestations. Rarely, in
its most severe form, MVT will present with peritonitis
and catastrophic bowel necrosis. Far more common,
however, it has an insidious presentation and is often a
harbinger of an underlying disorder. Here, a case of
MVT is presented as the initial manifestation of an occult
myeloproliferative disorder (MPD). Despite relatively
normal peripheral blood counts, the diagnosis was
made by the analysis of the gene expressing Janus kinase 2
(JAK2) that revealed a V617F point mutation. The JAK2
V617F mutation results in growth factor-independent prolif-
eration of hematopoietic cell lines and is diagnostic of an
MPD.1
CASE REPORT
A 65-year-old man presented with abdominal pain of 1-week
duration. The pain was periumbilical and constant, although exac-
erbated in the postprandial period, and accompanied by abdominal
fullness and anorexia. There was no history of nausea, vomiting, or
diarrhea. The patient had a history of type II diabetes mellitus,
hyperlipidemia, and chronic kidney disease, with a baseline creati-
nine level of 1.4 mg/dL. He had no history of deep venous
thrombosis or thrombophilia.
On physical examination, he was afebrile and his vital signs
were normal. He was not in acute distress, and his sclerae were
anicteric. His abdomen demonstrated mild tympany and mild
diffuse tenderness but no peritoneal signs. Laboratory analysis
showed levels of hemoglobin at 13.6 mg/dL, white blood cell
From the Division of Vascular and Endovascular Surgery, University of
California San Francisco.
Competition of interest: none.
Correspondence: Christopher D. Owens, MD, MSc, University of Califor-
nia San Francisco, Division of Vascular and Endovascular Surgery, 400
Parnassus Ave, San Francisco, CA 94143 (e-mail: Christopher.owens@
ucsfmedctr.org).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a competition of
interest.
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.01.097(WBC) count of 11,600 mm3 with 8.25% neutrophils, and the
platelet count was 685,000/mm3. After initial fluid resuscita-
tion, his platelet count returned to within normal reference
ranges (450,000/mm3). The remainder of his blood chemistry
values, including amylase and lipase, were within normal refer-
ence ranges.
After prehydration, an intravenous contrast-enhanced com-
puted tomography scan at admission revealed hepatosplenomeg-
aly, with an 8-  7-cm mass at the inferior border of the spleen
containing a fluid density surrounded by a chronic, thin-walled,
nonenhancing capsule that was thought to be liquefaction due to
infarction of the spleen. There was complete thrombosis of the
portal and splenic vein, with involvement of the proximal segment
of the superior mesenteric vein (Fig). He was admitted, anticoag-
ulated with unfractionated heparin, and placed on bowel rest.
A 10F pigtail catheter was inserted into the splenic fluid
collection, and 140mL of bloody fluid was aspirated. Gram stain of
the aspirate revealed3 white blood cells but no microorganisms.
No aerobic or anaerobic growth was noted from the aspirate after
5 days. Blood cultures obtained at the time of admission were
likewise negative for growth.
A peripheral smear revealed normochromic, normocytic ane-
mia with mild anisopoikilocytosis. The WBC and platelet counts
were within normal reference ranges, and there was no peripheral
evidence for myelofibrosis. He was tested for anticardiolipin anti-
body, isotypes immunoglobulin (Ig) G, IgM, and IgA, which were
negative, and for JAK2 mutation, which was positive for
Val617Phe (V617P) genotype.
A bone marrow aspirate revealed maturing trilineage hemato-
poietic components consisting predominantly of granulocytic
cells. The cellularity of the bone marrow was approximately 60%
(normal for a patient age 65 is about 45%). The myeloid (M)/
erythroid (E) ratio was increased to approximately 5-8:1 (normal
range, 2-4:1) and the megakaryocytes were increased in number. A
diagnosis of myeloproliferative disorder (MPD) was made given
the hypercellular bone marrow, the increased M:E ratio, and the
increase in megakaryocytes. The presence of the JAK2 V617F
mutation and the history of thrombocytosis were thought to be
most suggestive of evolving essential thrombocythemia.
The patient was prescribed Coumadin (Bristol-Myers Squibb,
Princeton, NJ) therapy with a goal international normalized ratio
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thrombotic events.
DISCUSSION
Patients withMVTmay present with a variety of clinical
manifestations, depending largely on the extent of the
thrombus, the size of the vessels involved, and the depth of
bowel wall ischemia. Patients with subacute presentations,
such as in this patient, often have periumbical pain that
suggests an origin in the midgut, but full-thickness bowel
ischemia is not likely. Once the diagnosis of MVT has been
made, associated casual pathology should be sought. Inflam-
matory diseases such as pancreatitis and inflammatory bowel
syndrome are usually easily detected by history, and postop-
erative states, cirrhosis, and trauma are obvious. However, in
the absence of obvious etiology, hematologic states involving
thrombophilia should be investigated (Table).
Many thrombophilic abnormalities are associated with
gain-of-function mutations such as factor V Leiden,
A20210G prothrombin, or clonal disorders involving the
hematopoietic system such the MPDs. The diagnosis of
thrombophilia is relatively straightforward, and the treat-
ment is generally anticoagulation. The diagnosis of MPD,
Fig. A multiplanar, contrast-enhanced, computed tomography
scan demonstrates thrombosis of the portal and splenic veins as
well as the proximal superior mesenteric vein (blue arrows) in a
65-year-old man with mild thrombocytosis and otherwise normal
peripheral blood counts. The distal superior mesenteric vein is
unaffected (red arrowhead). An 8-  7-cm fluid-filled collection
noted at the inferior border of the spleen was determined to be
liquefaction due to infarction (white arrow). A diagnosis of essen-
tial thrombocytosis was made after the patient tested positive for
the JAK2 V617F mutation.however, can be problematic at the time of acute thrombo-sis due to hemodilution, occult bleeding, and hyper-
splenism and therefore may delay appropriate cytoreductive
therapy. This is especially pertinent because MPD is prev-
alent in patients who present with MVT.
The MPDs can be broadly classified into Philadelphia
chromosome-positive (chronic myelogenous leukemia)
and Philadelphia chromosome-negative (polycythemia
vera, essential thrombocytosis, and myelofibrosis). Throm-
bosis and transformation to acute myeloid leukemia are the
major causes of morbidity andmortality in these disorders.2
MVT is the first clinical manifestation in an estimated 25%
to 78% of patients with newly diagnosed polycythemia vera
or essential thrombocytosis and often occurs before a rise in
peripheral blood counts.3,4 An accurate diagnosis of an
MPD historically has been supported by expensive and
invasive tests such as bone marrow biopsy and endogenous
erythroid colony formation assessment.
Recently, a point mutation in the JAK2 gene encoding
a valine to phenylalanine change at position 617 has been
found.5 The JAK2 V617F genotype confers constitutive
tyrosine kinase activation (gain-of-function) in patients
with sporadicMPDs.6 JAK2 is a cytoplasmic tyrosine kinase
that transduces signals by growth factors such as erythro-
poietin in normal and neoplastic cells. This change in a
single amino acid renders the JAK2 enzyme constitutively
active, leading to unregulated proliferation of hematopoi-
etic cell lines. The mutation can be detected in peripheral
blood cells by a commercially available qualitative RNA-
based, polymerase chain reaction sequencing assay (Speci-
ality Laboratories, Inc, Valencia, Calif). This mutation is
found in 95% of patients with polycythemia vera and in 50%
to 60% of the patients with essential thrombocytosis and
primary meylofibrosis.2 Patients with polycythemia vera or
essential thrombocytosis and the JAK2 V617F genotype
have a higher rate of thrombosis than patients with the
wild-type counterparts. A recent meta-analysis has deter-
mined a 32% overall prevalence of the JAK2 V617F muta-
tion in patients presenting with MVT.3 Therefore, these
data suggest that patients with MVT, with no other precip-
itating etiology, should be screened for the presence of the
JAK2 V617F mutation, because the finding of this muta-
Table. Prothrombotic disorders associated with
mesenteric venous thrombosis
Disorder Relative frequency
Antithrombin II deficiency Rare
Protein C deficiency Rare
Protein S deficiency Infrequent
G1691A factor V (Leiden) mutation Rare
G20210A mutation in prothrombin gene Infrequent
MTHFR C677T gene mutation Rare
JAK2 V617F gene mutation Frequent
JAK2 V617F, Janus-activated kinase gain-of-function substitute of valine to
phenylalanine at position 617; MTHFR, methylenetetrahydrofolate reduc-
tase.tion is diagnostic of an occult MPD.
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prevalent in patients with other venous thrombosis disor-
ders such as deep vein thrombosis (DVT) or pulmonary
embolism than in healthy control populations. A recent
review reported that a JAK2 V617Fmutation was found in
two patients with recurrent arterial thromboembolism,
both of whom were subsequently diagnosed with MPD.7
Although widespread testing for the mutation in patients
presenting with DVT cannot be endorsed, testing for the
JAK2 V617F mutation may be warranted for patients with
refractory thrombotic events and an otherwise negative
hematologic workup.
Why the JAK V617Fmutation is so strongly associated
with MVT but not in lower extremity venous thrombosis is
unknown. It is possible that MPD affects the blood flow
through the mesenteric venous bed and therefore makes
this location particularly prone to thrombosis. It has been
shown that platelets from patients with the JA2 V617F
mutation express P-selectin more easily than wild-type con-
trols, which may contribute to thrombosis.8 Other possi-
bilities include an association with the JAK2 V617F muta-
tion and higher levels of peripheral erythrocytes andWBCs,
thereby increasing blood viscosity.9
CONCLUSIONS
The diagnosis of MVTmay be the first manifestation of
an occult MPD that can occur even in the setting of
peripheral blood counts within the normal reference range
where suspicion would otherwise be low. The JAK2 V617F
mutation is present in about one-third of patients with
MVT and is diagnostic of an MPD. Therefore, knowledgeof this genetic association will permit prompt diagnosis,
possibly without the need for unnecessary invasive tests
such as bone biopsy, and allow for the timely initiation of
cytoreductive therapy.
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